摘要
目的:了解表浅性膀胱癌患者术后口服人参皂甙Rg3(SPG Rg3)联合丝裂霉素C(MMC)膀胱内灌注后血清中血管内皮细胞生长因子(VEGF)的浓度并探讨其临床意义。方法:将65例表浅性膀胱癌患者随机分为MMC治疗组和MMC+人参皂甙Rg3治疗组。采用流式细胞仪测定2组患者术前、辅助治疗前及辅助治疗后2个月血清VEGF浓度,同时测定30例健康成人血清VEGF浓度。结果:术前表浅性膀胱癌患者血清VEGF水平(258.0±185.1)pg.mL-1明显高于健康成人(163.1±95.5)pg.mL-1(P<0.01);辅助治疗后2个月Rg3+MMC治疗组血清VEGF水平(183.8±107.1)pg.mL-1明显低于单纯MMC治疗组(246.4±177.5)pg.mL-1(P<0.05)。结论:表浅性膀胱癌患者血清VEGF水平明显高于健康人,血清VEGF水平可作为反映表浅性膀胱癌生物学行为的指标之一;采用口服人参皂甙Rg3联合MMC膀胱内灌注能明显降低表浅性膀胱癌患者术后血清VEGF水平,从而有可能进一步降低表浅性膀胱癌的复发率。
Objective：To evaluate the effects of the concentration of serum VEGF by ginsenoside Rg3 combined with intravesical instillation mitomycin C on postoperative chemotherapy in superficial bladder cancer.Methods：Sixty-five patients were divided into two groups randomly ： mitomycin C（n=33） and ginsenoside Rg3 combined with mitomycin C（n=32）.The concentration of serum VEGF at preoperative,pretherapy and post-treatment two months were detected by Partec Flowcytometery（FCM）,The concentration of serum VEGF of thirty normal people were detected simultaneously.Results：The levels of serum VEGF of patients（258.0士185.1） pg/ml were much higher than the normal people（163.1±95.5） pg/ml（P 0.01）;The levels of serum VEGF in the Rg3＋MMC group（183.8±107.1）pg/ml were much lower than the MMC group（246.4±177.5）pg/ml after two months（P0.05）.Conclusions： The combined application of ginsenoside Rg3 ＋MMC chemotherapy can decrease the concentration of serum VEGF and may reduce the rate of the bladder cancer recurrence.
出处
《中国临床医学》
2010年第5期727-728,共2页
Chinese Journal of Clinical Medicine
基金
江苏大学科技发展基金(编号:20050039)
